Peron J - Search Results

1

Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7).

Colomban O, Tod M, Peron J, Perren TJ, Leary A, Cook AD, Sajous C, Freyer G, You B. Colomban O, et al. Among authors: peron j. JNCI Cancer Spectr. 2020 Apr 4;4(3):pkaa026. doi: 10.1093/jncics/pkaa026. eCollection 2020 Jun. JNCI Cancer Spectr. 2020. PMID: 32596636 Free PMC article.

2

Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.

Freyer G, Campone M, Peron J, Facchini T, Terret C, Berdah JF, Jacquin JP, Coeffic D, Hilaire Pde S, Falandry C. Freyer G, et al. Among authors: peron j. Crit Rev Oncol Hematol. 2011 Dec;80(3):466-73. doi: 10.1016/j.critrevonc.2011.04.001. Epub 2011 May 11. Crit Rev Oncol Hematol. 2011. PMID: 21565521

3

Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review.

Péron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B. Péron J, et al. J Natl Cancer Inst. 2012 Jul 3;104(13):982-9. doi: 10.1093/jnci/djs259. Epub 2012 Jul 3. J Natl Cancer Inst. 2012. PMID: 22761273 Review.

4

Influence of statistician involvement on reporting of randomized clinical trials in medical oncology.

Péron J, You B, Gan HK, Maillet D, Chen EX, Pond GR. Péron J, et al. Anticancer Drugs. 2013 Mar;24(3):306-9. doi: 10.1097/CAD.0b013e32835c3561. Anticancer Drugs. 2013. PMID: 23221738

5

Response.

Péron J, You B. Péron J, et al. J Natl Cancer Inst. 2013 Feb 6;105(3):244-5. doi: 10.1093/jnci/djs511. J Natl Cancer Inst. 2013. PMID: 23520607 No abstract available.

6

Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.

Péron J, Maillet D, Gan HK, Chen EX, You B. Péron J, et al. J Clin Oncol. 2013 Nov 1;31(31):3957-63. doi: 10.1200/JCO.2013.49.3981. Epub 2013 Sep 23. J Clin Oncol. 2013. PMID: 24062406 Review.

7

Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy.

Bylicki O, Gan HK, Joly F, Maillet D, You B, Péron J. Bylicki O, et al. Among authors: peron j. Ann Oncol. 2015 Jan;26(1):231-237. doi: 10.1093/annonc/mdu489. Epub 2014 Oct 29. Ann Oncol. 2015. PMID: 25355720 Free article.

8

The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.

Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J. Maillet D, et al. Among authors: peron j. Ann Oncol. 2016 Jan;27(1):192-8. doi: 10.1093/annonc/mdv485. Epub 2015 Oct 19. Ann Oncol. 2016. PMID: 26483049 Free article.

9

Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.

Maillet D, Gan HK, Blay JY, You B, Péron J. Maillet D, et al. Among authors: peron j. Eur J Cancer. 2016 Jan;52:26-32. doi: 10.1016/j.ejca.2015.08.025. Epub 2015 Nov 27. Eur J Cancer. 2016. PMID: 26630531 Review.

10

Inclusion of elderly patients in oncology clinical trials.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J. Le Saux O, et al. Among authors: peron j. Ann Oncol. 2016 Sep;27(9):1799-804. doi: 10.1093/annonc/mdw259. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358382 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

600 results

Search Page

Filters